JP2008525479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525479A5 JP2008525479A5 JP2007548477A JP2007548477A JP2008525479A5 JP 2008525479 A5 JP2008525479 A5 JP 2008525479A5 JP 2007548477 A JP2007548477 A JP 2007548477A JP 2007548477 A JP2007548477 A JP 2007548477A JP 2008525479 A5 JP2008525479 A5 JP 2008525479A5
- Authority
- JP
- Japan
- Prior art keywords
- tff
- seq
- compound
- antagonist
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010007389 Trefoil Factors Proteins 0.000 claims 28
- 102000007641 Trefoil Factors Human genes 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 6
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 102000008816 Trefoil Factor-2 Human genes 0.000 claims 5
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 4
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 101150053753 TFF1 gene Proteins 0.000 claims 3
- 101150048087 TFF3 gene Proteins 0.000 claims 3
- 101150115851 Tff2 gene Proteins 0.000 claims 3
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000006471 dimerization reaction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000005714 functional activity Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002452 interceptive effect Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 229960001603 tamoxifen Drugs 0.000 claims 3
- 208000010305 Epidermal Cyst Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 108010088411 Trefoil Factor-2 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940083963 Peptide antagonist Drugs 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 208000017338 epidermoid cysts Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 206010049444 fibromatosis Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 208000029513 osteogenic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004907226A AU2004907226A0 (en) | 2004-12-22 | TFF3 antagonists | |
| AU2004907263A AU2004907263A0 (en) | 2004-12-22 | Methods of treatment | |
| AU2004907262A AU2004907262A0 (en) | 2004-12-22 | Methods of treatment | |
| PCT/US2005/046634 WO2006069253A2 (en) | 2004-12-22 | 2005-12-22 | Trefoil factors and methods of treating proliferation disorders using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013251639A Division JP2014088393A (ja) | 2004-12-22 | 2013-12-05 | トレフォイル因子およびそれを用いた増殖性疾患の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008525479A JP2008525479A (ja) | 2008-07-17 |
| JP2008525479A5 true JP2008525479A5 (enExample) | 2009-02-12 |
Family
ID=36602332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548477A Pending JP2008525479A (ja) | 2004-12-22 | 2005-12-22 | トレフォイル因子およびそれを用いた増殖性疾患の処置方法 |
| JP2013251639A Pending JP2014088393A (ja) | 2004-12-22 | 2013-12-05 | トレフォイル因子およびそれを用いた増殖性疾患の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013251639A Pending JP2014088393A (ja) | 2004-12-22 | 2013-12-05 | トレフォイル因子およびそれを用いた増殖性疾患の処置方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20090022708A1 (enExample) |
| EP (1) | EP1833991A4 (enExample) |
| JP (2) | JP2008525479A (enExample) |
| NZ (1) | NZ556158A (enExample) |
| WO (1) | WO2006069253A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2084539A4 (en) * | 2006-10-03 | 2010-09-08 | Neuren Pharmaceuticals Ltd | TREFOIL FACTORS BINDING CONFORMATION-SPECIFIC ANTIBODIES AND METHODS FOR TREATING CANCER DISEASES AND PROLIFERATION DISORDERS THEREWITH |
| US20090304700A1 (en) * | 2008-06-06 | 2009-12-10 | Neuren Pharmaceuticals, Ltd. | Conformation specific antibodies that bind trefoil factors |
| WO2011068865A1 (en) * | 2009-12-01 | 2011-06-09 | Board Of Trustees Of Southern Illinois University | Micro-rna-101 promotes estrogen-independent growth and confers tamoxifen resistance in er-positive cancer cells |
| US20130274171A1 (en) | 2010-06-04 | 2013-10-17 | Trifoilium Aps | Trefoil factors (tff) for the treatment of chronic pulmonary diseases |
| WO2012038825A2 (en) * | 2010-09-21 | 2012-03-29 | Auckland Uniservices Limited | Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (tff1) |
| WO2012150869A1 (en) * | 2011-05-05 | 2012-11-08 | Neuren Pharmaceuticals Limited | Antibodies that bind trefoil factors and methods of using same |
| AU2013259486B2 (en) * | 2012-05-09 | 2019-12-12 | Hong Kong Baptist University | Method and compounds for inhibiting the MCM complex and their application in cancer treatment |
| KR102291465B1 (ko) * | 2014-01-24 | 2021-08-18 | 삼성전자주식회사 | c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1 |
| CN110869386A (zh) * | 2017-02-10 | 2020-03-06 | 维维巴巴公司 | 重组神经生长因子的组合物和方法 |
| CN115551530A (zh) * | 2019-08-27 | 2022-12-30 | 通尼克斯制药有限公司 | 经修饰的tff2多肽 |
| WO2022240649A1 (en) * | 2021-05-12 | 2022-11-17 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators |
| TW202134275A (zh) * | 2019-11-26 | 2021-09-16 | 美商長青之泉股份有限公司 | 用於以三葉因子家族成員２調節劑治療衰老相關性障礙的方法和組合物 |
| CN113721019A (zh) * | 2021-09-05 | 2021-11-30 | 苏州银湾细胞生物科技有限公司 | 胆管癌术后生存预测方法、试剂盒以及试剂盒的应用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US650559A (en) * | 1900-01-31 | 1900-05-29 | American Type Founders Co | Gas-burner. |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
| DE69231385T2 (de) | 1991-06-05 | 2001-04-12 | The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
| WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
| WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
| US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO2001051628A2 (en) * | 2000-01-14 | 2001-07-19 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20030125265A1 (en) * | 2001-05-09 | 2003-07-03 | Mien-Chie Hung | Anti-estrogen receptor agents for chemotherapy |
| US20030193682A1 (en) * | 2002-04-10 | 2003-10-16 | Parry Travis J. | Method and system for partitioning multiple media handling jobs |
| JP2004534801A (ja) * | 2001-06-14 | 2004-11-18 | ノボ ノルディスク アクティーゼルスカブ | Ｔｆｆ２ペプチドによる粘膜修復 |
| WO2002102403A1 (en) * | 2001-06-14 | 2002-12-27 | Novo Nordisk A/S | Mucosal repair by tff dimer peptides |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20030215431A1 (en) * | 2002-02-11 | 2003-11-20 | Lars Thim | Management of mucosal viscosity by TFF monomer peptides |
| DE10215320A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Verwendungen von TFF3 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen |
| AU2003286844A1 (en) * | 2002-10-31 | 2004-05-25 | The General Hospital Corporation | Trefoil domain-containing polypeptides and uses thereof |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| KR20060073589A (ko) * | 2003-08-07 | 2006-06-28 | 카이론 코포레이션 | 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3) |
| WO2005042010A1 (en) * | 2003-10-30 | 2005-05-12 | Novo Nordisk A/S | Use of trefoil polypeptides in the treatment of diabetes |
-
2005
- 2005-12-22 US US11/794,025 patent/US20090022708A1/en not_active Abandoned
- 2005-12-22 WO PCT/US2005/046634 patent/WO2006069253A2/en not_active Ceased
- 2005-12-22 NZ NZ556158A patent/NZ556158A/en not_active IP Right Cessation
- 2005-12-22 JP JP2007548477A patent/JP2008525479A/ja active Pending
- 2005-12-22 EP EP05855229A patent/EP1833991A4/en not_active Withdrawn
-
2010
- 2010-01-04 US US12/651,850 patent/US20100129370A1/en not_active Abandoned
-
2013
- 2013-12-05 JP JP2013251639A patent/JP2014088393A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roswall et al. | Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling | |
| KR102240323B1 (ko) | 유방암 전이의 진단, 예후 및 치료 방법 | |
| KR102252332B1 (ko) | 암 전이의 예후 및 치료 방법 | |
| Feng et al. | Lin28 regulates HER2 and promotes malignancy through multiple mechanisms | |
| Alifano et al. | Neurotensin receptor 1 determines the outcome of non–small cell lung cancer | |
| Michaelson et al. | Tweak induces mammary epithelial branching morphogenesis | |
| US10705087B2 (en) | Detection method for NTRK3 fusion | |
| JP2008525479A5 (enExample) | ||
| JP2012522756A5 (enExample) | ||
| JP2018078911A5 (enExample) | ||
| JP2019518452A5 (enExample) | ||
| JP2016516403A5 (enExample) | ||
| JP2016105731A5 (enExample) | ||
| JP2014503180A5 (enExample) | ||
| Shimizu et al. | Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin‐neurotensin receptor 1 oncogenic signaling pathway | |
| JP2012501164A5 (enExample) | ||
| KR101811731B1 (ko) | Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도 | |
| JP2019523641A5 (enExample) | ||
| Mohammed et al. | The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis | |
| Geismann et al. | Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-β1 (TGF-β)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells | |
| Li et al. | Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization | |
| JP2013503644A5 (enExample) | ||
| JP2010131022A5 (enExample) | ||
| JP6673698B2 (ja) | 新規のｅｇｆｒ変異体 | |
| Dekanić et al. | Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification |